Abstract:The immune system plays a crucial role in cancer development either by fostering tumor growth or destroying tumor cells, which has open new avenues for cancer immunotherapy. It was only over the last decade that the role of B cells in controlling anti-tumor immune responses in the tumor milieu has begun to be appreciated. B and plasma cells can exert anti-tumor effects through antibody-dependent cell cytotoxicity (ADCC) and activation of the complement cascade, even though their effector functions extend beyond the classical humoral immunity. In tumor tissues, B cells can be found in lymphoid aggregates, known as tertiary lymphoid structures (TLSs), well-organized non-encapsulated structures composed of immune and stromal cells. These structures reflect a process of lymphoid neogenesis occurring in peripheral tissues upon long-lasting exposure to inflammatory signals. The TLS provides an area of intense B cell antigen presentation that can lead to optimal T cell activation and effector functions, as well as the generation of effector B cells, which can be further differentiated in either antibody-secreting plasma cells or memory B cells. Of clinical interest, the crosstalk between B cells and antigen-experienced and exhausted CD8 + T cells within mature TLS was recently associated with improved response to immune checkpoint blockade (ICB) in melanoma, sarcoma and lung cancer. Otherwise, B cells sparsely distributed in the tumor microenvironment or organized in immature TLSs were found to exert immune-regulatory functions, inhibiting anti-tumor immunity through the secretion of anti-inflammatory cytokines. Such phenotype might arise when B cells interact with malignant cells rather than T and dendritic cells. Differences in the spatial distribution likely underlie discrepancies between the role of B cells inferred from human samples or mouse models. Many fast-growing orthotopic tumors develop a malignant cell-rich bulk with reduced stroma and are devoid of TLSs, which highlights the importance of carefully selecting pre-clinical models. In summary, strategies that promote TLS formation in close proximity to tumor cells are likely to favor immunotherapy responses. Here, the cellular and molecular programs coordinating B cell development, activation and organization within TLSs will be reviewed, focusing on their translational relevance to cancer immunotherapy.

Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?

Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity

Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?

B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers

Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy

Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers

Tertiary lymphoid structures and B cells: An intratumoral immunity cycle

Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer

Neglected no more: B cell-mediated anti-tumor immunity

Tertiary lymphoid structures in the era of cancer immunotherapy

Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?

Tertiary lymphoid structures in anticancer immunity

Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation

Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer

Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies

Mechanisms of tertiary lymphoid structure formation: cooperation between inflammation and antigenicity

Tertiary lymphoid structures and their therapeutic implications in cancer

Tertiary Lymphoid Structure-Associated B Cells Enhance Response to Programmed Cell Death Protein 1 Blockade in Cancer Immunotherapy

Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity

Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients